financing

The firm offered more than 2.7 million shares of its common stock, including 356,435 shares to its underwriters pursuant to an option to purchase additional shares.

The firm it plans to offer from time to time units of its common stock, preferred stock, one or more debt securities, warrants, or rights to such securities in one or more series.

The firm will use the funding to begin a validation study of its blood-based test for early detection of colorectal cancer. 

The firm will use the proceeds to continue developing its Proteograph platform, build its proteomic database, and develop liquid biopsy products for early disease detection.

The firm is using automated laboratory testing, artificial intelligence, and single-cell omics for a "precision" approach to cancer drug discovery.

The San Diego-based firm emerged from stealth mode with a plan to develop technologies to improve the quality and reduce the cost of genetic analysis.

The company said it will use the funding to accelerate the launch of its core isotachophoresis platform for nucleic acid sample preparation.

With $46 million in total raised since its founding in 2016, the company hopes to scale its telegenetics services to meet national demand.

The firm will use the funding for working capital for the Cyto-Mine single-cell analysis platform, UK facility expansion, and a new US sales office and demo lab.

The company is commercializing a method developed by researchers at Johns Hopkins that detects cancer with high specificity from a blood sample.